Micardis
Links shared publicly online about this topic
FDA gives Micardis wider approval
healthcentral.com — “FDA gives Micardis wider approval” View full resource at healthcentral.com
Most Recently Shared on October 21, 2009 at 3:46 pm By:
healthcentral: FDA gives Micardis wider approval http://bit.ly/1xUISY Full http://bit.ly/30K9QS
Symposier - FDA Approves MICARDIS® (Telmisartan)
symposier.com — “Uploaded and Shared in Youtube by:BusinessWire Prof. Thomas Unger, Germany (Video: Business Wire) Permalink: http://www.businesswire.com...” View full resource at symposier.com
Most Recently Shared on December 2, 2009 at 4:58 am By:
Symposier Cardiology Cardiology and Health Business
FDA Approves MICARDIS® (Telmisartan) -->http://bit.ly/8Oynvf #red WAIDSDAY
Telmisartan (Micardis) Drug Information by MedicineNet.com
medicinenet.com — “Telmisartan (micardis) is an arb prescribed for the treatment of high blood pressure and the prevention of heart attack, stroke, and cardiovascular events in patients at risk.” View full resource at medicinenet.com
Most Recently Shared on January 7, 2010 at 6:45 pm By:
MedicineNet: telmisartan, Micardis http://bit.ly/64aggw Full http://bit.ly/7AQcW1
European Commission approves MICARDIS medication for CV protection
news-medical.net — “MICARDIS® is the first treatment in its class to be approved for this indication. The EMEA approval is the second major milestone for MICARDIS® in cardiovascular protection. It follows the approval by the US FDA for the reduction of the risk of myocardial infarction (heart attack), stroke, or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take ACE inhibitors.” View full resource at news-medical.net
Most Recently Shared on November 27, 2009 at 12:40 pm By:
Stroke News: European Commission approves MICARDIS medication for CV protection: MICARDIS® is the first treatmen... http://twurl.nl/fa5ea3
Micardis Given Wider Approval - Drugs.com MedNews
drugs.com — “Micardis (telmisartan) has received expanded approval from the U.S. Food and Drug Administration to reduce the risk of heart attack or stroke in people 55 or ol” View full resource at drugs.com
Most Recently Shared on October 19, 2009 at 10:26 pm By:
Micardis Given Wider Approval - http://bit.ly/1X0mkQ
Major European Regulatory Milestone In Cardiovascular Protection For MICARDIS(R) (telmisartan)
medicalnewstoday.com — “Boehringer ingelheim announced that the european commission has approved micardis® (telmisartan) for the reduction of cardiovascular morbidity in patients with: i. manifest atherothro” View full resource at medicalnewstoday.com
Most Recently Shared on November 30, 2009 at 11:13 am By:
MedicalNewsToday: Major European Regulatory Milestone In Cardiovascular Protection For: http://bit.ly/4WXeiu Full http://bit.ly/8vkJa9
Boehringer denies Micardis cancer link | InPharm
inpharm.com — “Boehringer denies Micardis cancer link | InPharm” View full resource at inpharm.com
Most Recently Shared on June 14, 2010 at 10:05 am By:
Pharmafocus Health News and Pharma
Boehringer denies Micardis cancer link http://ht.ly/1Y3Tf
Boehringer Ingelheim receives European CHMP positive opinion for MICARDIS
news-medical.net — “Boehringer Ingelheim announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Evaluation Agency (EMEA) has issued a positive opinion for the approval of MICARDIS® (telmisartan) for the reduction of cardiovascular morbidity.” View full resource at news-medical.net
Most Recently Shared on October 23, 2009 at 9:58 pm By:
Stroke News: Boehringer Ingelheim receives European CHMP positive opinion for MICARDIS: Boehringer .. http://twurl.nl/opbfak
FDA approves Boehringer Ingelheim's MICARDIS for the reduction of risk of heart attack
news-medical.net — “Boehringer Ingelheim announced today that the US Food and Drug Administration (FDA) has approved a new indication for MICARDIS® (telmisartan) for the reduction of the risk of myocardial infarction (heart attack), stroke, or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take ACE inhibitors. MICARDIS® is the first treatment in its class to be approved for this indication.” View full resource at news-medical.net
Most Recently Shared on October 19, 2009 at 5:06 pm By:
Stroke News: FDA approves Boehringer Ingelheim's MICARDIS for the reduction of risk of heart attack:.. http://twurl.nl/n1anwp
Micardis 80mg gains indication for cardiovascular risk reduction - MPR
empr.com — “The FDA has approved Micardis 80mg (telmisartan tablets, from Boehringer Ingelheim), an angiotensin II receptor blocker (ARB), for the reduction of the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients 55 years of age at high risk of developing major cardiovascular events who are unable to take angiotensin-converting enzyme inhibitors (ACE inhibitors).” View full resource at empr.com
Most Recently Shared on October 19, 2009 at 3:41 pm By:
MPR News: Micardis 80mg gains indication for cardiovascular risk reduction: The FDA has approved Micard.. http://bit.ly/zbBaI
MICARDIS receives Health Canada approval to reduce the risk of non-fatal stroke
news-medical.net — “MICARDIS(R) (telmisartan) has received Health Canada approval to reduce the risk of non-fatal stroke or non-fatal myocardial infarction in patients 55 years or older at high risk of developing major cardiovascular events who cannot tolerate an angiotensin converting enzyme (ACE) inhibitor.” View full resource at news-medical.net
Most Recently Shared on November 27, 2009 at 6:39 am By:
Stroke News: MICARDIS receives Health Canada approval to reduce the risk of non-fatal stroke: MICARDIS(R) (telmis... http://twurl.nl/7q1hs2
Boehringer Ingelheim Pharmaceuticals receives NDA approval from FDA for its Micardis Tablets 80 mg
news-medical.net — “Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for its angiotensin II receptor blocker (ARB) Micardis® (telmisartan) Tablets 80 mg for reduction of the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients 55 years of age or older at high risk of developing major cardiovascular events who are unable to take angiotensin-converting enzyme (ACE) in” View full resource at news-medical.net
Most Recently Shared on October 19, 2009 at 5:06 pm By:
Stroke News: Boehringer Ingelheim Pharmaceuticals receives NDA approval from FDA for its Micardis Ta.. http://twurl.nl/oswp1h
Comments of using Micardis, Prozac, Kapidex, Prednisone, Rapaflo (study 6153968) - eHealthMe.com
ehealthme.com — “Rapaflo worked immediately (10 minutes) within 24 hrs. Sharp pelvic/hip pain subsided. Then it seemed to activate more stones. Could not tolerate headache. Felt like a hypertensive/migraine like headache with rapid onset. How safe is this medicine for women? If lower dose works how long should it be used before surgical intervention is sought?” View full resource at ehealthme.com
Most Recently Shared on March 23, 2012 at 2:52 am By:
Rapaflo worked immediately (10 minutes) within 24 hrs. Sharp pelvic/hip pain subsided. Then it seemed to acti http://t.co/2b5Uw8eM
FDA Approves New Use for Micardis(R) in Cardiovascular Risk Reduction and Twynsta(R) as New Combination Treatment for High Blood Pressure | Reuters
reuters.com — “FDA Approves New Use for Micardis(R) in Cardiovascular Risk Reduction and Twynsta(R) as New Combination Treatment for High Blood Pressure MICARDIS is First ARB Indicated to Reduce Risk of Cardiovascular” View full resource at reuters.com
Most Recently Shared on October 19, 2009 at 1:59 pm By:
Tammi Jacobs Health Professional
FDA Approves New Use for Micardis(R) in Cardiovascular Risk Reduction and ... http://bit.ly/2yT1Qw
Micardis satisfaction and usage data | Monitoring more than 2,800 patients | Drug safety information | MediGuard
mediguard.org — “Micardis satisfaction and usage data | Monitoring more than 2,800 patients | Drug safety information | MediGuard” View full resource at mediguard.org
Most Recently Shared on May 28, 2011 at 7:17 pm By:
MediGuard.org Health Organization
Unsatisfied. 22% of #micardis patients wish they were told more before starting http://tinyurl.com/3vxgvt8
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
Heart Health
Get the latest news, information, and research on your heart. Re-tweet if you want.
-
Symposier Cardiology
Symposier.com, the technological platform that will allow you (and your colleagues) to share medical information, and much more with medicine professionals.
-
Heart Health
Get the latest news, information, and research on your heart. Re-tweet if you want.
Advertisement
